Clinical trials
Atopic Dermatitis clinical trials
Below are recruiting atopic dermatitis clinical trials, each written for real people, not researchers. We’re tracking 183 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05735483Enrolling by invitationPhase 3
Long-term lebrikizumab study for moderate to severe eczema
This Phase 3 trial studies whether lebrikizumab is safe and continues to work over the long term for children and teens with moderate-to-severe atopic dermatitis (eczema). It’s meant for people who already finished a related earlier study and can safely continue.
Birmingham, AlabamaAges 6 months–18 years - NCT04419584RecruitingPhase 2/Phase 3
Modified Qing-Ying decoction for children with eczema
This trial tests a traditional Chinese herbal formula (Modified Qing-Ying Decoction) for children ages 4 to 17 with moderate-to-severe eczema (atopic dermatitis). The study aims to see if this herbal treatment can improve skin dryness, redness, and itching, especially for those with dry, scaly patches.
Hong KongAges 4–17 - NCT07239947RecruitingPhase 1
Testing BBT001 for healthy volunteers and people with eczema
This trial tests a new medicine called BBT001, first in healthy people and then in adults with moderate to severe eczema (atopic dermatitis). It aims to see if the drug is safe and how well it works for treating eczema that hasn't improved with topical treatments.
Hefei, AnhuiAges 18–65 - NCT05575882Recruiting
Skin cream trial to prevent relapses in very dry eczema skin
This trial tests whether a cosmetic cream can reduce eczema flare-ups and is comfortable/safe to use on very dry, irritated, eczema-prone skin. It’s mainly for children who have had recent flare-ups and moderate eczema severity.
Ciudad Autónoma de Buenos Aire, Ciudad Autónoma de Buenos AireAges 6 months–15 years - NCT05674695Recruiting
Registry study for starting or switching atopic eczema medicines
This study follows people with atopic eczema when they start or switch to a specific medicine that affects the immune system. It helps doctors understand how these treatments work in real life, including for skin symptoms and daily quality of life.
Badalona, BarcelonaAges Any age - NCT05819463Recruiting
Study care for moderate to severe atopic dermatitis
This trial looks at treatment and medical care for teens and adults with moderate to severe atopic dermatitis (eczema). It may help by testing ways to manage symptoms better based on severity and current treatment needs.
BaselAges 12 years+ - NCT06808477RecruitingPhase 1
BBT001 for moderate to severe eczema
This trial tests an experimental drug called BBT001 for people with moderate to severe eczema (atopic dermatitis) that hasn't been helped enough by creams. The study is in early phases, so it will check how safe the drug is and how well it might work.
Irvine, CaliforniaAges 18–72 - NCT06837454Recruiting
Study of eczema patients on systemic therapy
This study follows adults with moderate to severe eczema who are eligible for or already taking systemic (pill or injection) medicines. It does not test any new drug—it simply tracks how eczema is managed in real life, which may help improve future care.
Aix-en-ProvenceAges 18 years+ - NCT06946641RecruitingPhase 1
Testing QLS12010 safety in healthy adults and people with eczema
This trial tests a new drug, QLS12010, to see if it is safe and how it works in healthy volunteers and in people with moderate to severe atopic dermatitis (eczema). It may offer a new treatment option for those whose eczema has not improved with topical creams.
BeijingAges 18–75 - NCT06998446Recruiting
Sodium in the skin and eczema study
This study looks at sodium levels in the skin of older adults with eczema. It uses an MRI scan to measure sodium and may help us understand how sodium affects eczema severity.
San Francisco, CaliforniaAges 50 years+ - NCT07488065RecruitingPhase 1
New drug for moderate to severe eczema
This trial tests a new injectable drug called SKB575 for people with moderate to severe atopic dermatitis (eczema). It aims to see how safe and effective the drug is, especially for those who haven't had success with strong creams or pills.
ShanghaiAges 18–70 - NCT07544862Recruiting
Stapokibart injection for atopic dermatitis in adults
This study tests a new injection medicine called Stapokibart for treating atopic dermatitis (a chronic skin condition causing itching and inflammation). Your doctor has already decided this medicine might help you before you joined the study.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07645820Recruiting
Testing a device to detect eczema flares early
This study tests a non-invasive home device called Nevisense Go that may help detect atopic dermatitis (eczema) flares before they become severe. You'll use the device at home, track your symptoms, and visit the clinic a few times to see if it helps predict when flares are coming.
Phoenix, ArizonaAges 12–89 - NCT06947252Enrolling by invitation
Food allergy test for kids with eczema avoiding certain foods
This trial tests if children with eczema who avoid certain foods actually have a food allergy. It uses a supervised oral food challenge to confirm.
BangkokAges Up to 6 years - NCT07754968Recruiting
Probiotic for formula-fed babies with colic
This study tests whether adding a probiotic called Bifidobacterium bifidum to formula can help reduce colic symptoms in babies who are not breastfed. It may also help if the baby has eczema (atopic dermatitis).
Roma, RMAges 1 week–5 months - NCT03361215Recruiting
Tracking skin disease patterns and anti-inflammatory response
This study looks at how atopic dermatitis (eczema), psoriasis, or other autoimmune skin diseases change over time and how the body responds to anti-inflammatory signals. Your information and—if eligible—samples help researchers find patterns that could guide better treatments.
KielAges birth–100 years - NCT06448689Recruiting
Wrist monitor study for itch in eczema and psoriasis
This study tests whether a wrist-worn device can accurately measure scratching during sleep in people with eczema (atopic dermatitis) or psoriasis. It may help doctors better understand and treat nighttime itching.
ParisAges 14–70 - NCT06982352RecruitingPhase 1
Testing safety of LPX-TI641 for eczema and psoriasis
This study tests a new drug called LPX-TI641 to see if it's safe and how it works in people with atopic dermatitis (eczema) or psoriasis. If you have moderate-to-severe symptoms that haven't been helped by standard creams, you might be able to join.
Fargo, North DakotaAges 18 years+ - NCT06504160RecruitingPhase 1
Testing a bacteria cream for eczema (TIME-2)
This study tests whether a cream made from a friendly skin bacteria (Staphylococcus hominis) can help treat eczema. Eligible participants will apply the cream to eczema patches on their arms, legs, or trunk for several weeks.
San Diego, CaliforniaAges 6 years+ - NCT05492578Enrolling by invitationPhase 2/Phase 3
Long-term follow-up of amlitelimab for moderate to severe eczema
This trial studies the long-term safety and effectiveness of amlitelimab in people with moderate to severe atopic dermatitis (eczema). You may be eligible if you previously joined an amlitelimab eczema study and are continuing into a longer follow-up phase.
Birmingham, AlabamaAges 12 years+ - NCT07527923RecruitingPhase 1
Testing REGN20423 for healthy people and atopic dermatitis
This early-stage trial tests a new experimental medicine called REGN20423 in two groups: healthy volunteers and people with atopic dermatitis (a chronic skin condition causing itching and inflammation). The trial aims to assess whether the medicine is safe and well-tolerated.
Leuven, Vlaams-BrabantAges 18–65 - NCT06723080RecruitingPhase 3
Oral VC005 for moderate to severe eczema
This study tests an investigational oral tablet (VC005) for adults with moderate to severe atopic dermatitis (eczema). It is for people whose eczema has not been controlled well enough with topical treatments.
Nanjing, JiangsuAges 18–75 - NCT07558668RecruitingPhase 1
Testing SYX-5219 for atopic dermatitis in healthy people and patients
This trial tests a new drug called SYX-5219 to see if it is safe and how the body handles it. Part 1 and 2 use healthy volunteers, while Part 3 tests it in people with moderate to severe atopic dermatitis (eczema). The goal is to understand if this drug might help treat eczema symptoms like itching and skin inflammation.
Arkansas City, ArkansasAges 18–65 - NCT06239311RecruitingPhase 3
Methotrexate vs placebo for adults with eczema
This trial tests if methotrexate, a medication that calms the immune system, can help adults with moderate-to-severe eczema that hasn't improved with creams or other treatments. You'll either receive methotrexate or a placebo to see which works better.
Prague, Praha 1Ages 18 years+
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for atopic dermatitis?
- Yes. Clin2 currently lists 183 recruiting atopic dermatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a atopic dermatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a atopic dermatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.